Rociletinib HBr is the salt form of Rociletinib, also known as AVL-301 and CO-1686, an orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Rociletinib binds to and inhibits mutant forms of EGFR, including T790M, thereby leading to cell death of resistant tumor cells. Rociletinib inhibits T790M, a secondary acquired resistance mutation, as well as other mutant EGFRs and may have therapeutic benefits in tumors with T790M-mediated resistance to other EGFR tyrosine kinase inhibitors.
MedKoo Cat#: 413217
Name: Rociletinib HBr
CAS#: 1446700-26-0 (HBr)
Chemical Formula: C27H29BrF3N7O3
Exact Mass: 0.0000
Molecular Weight: 636.47
Elemental Analysis: C, 50.95; H, 4.59; Br, 12.55; F, 8.95; N, 15.41; O, 7.54
The following data is based on the product molecular weight 636.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
